blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2985032

EP2985032 - GLYX FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE [Right-click to bookmark this link]
Former [2016/07]GLYX FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE, AIDS DEMENTIA, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE
[2018/30]
StatusNo opposition filed within time limit
Status updated on  08.11.2019
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  30.11.2018
FormerGrant of patent is intended
Status updated on  15.07.2018
FormerExamination is in progress
Status updated on  03.02.2017
FormerRequest for examination was made
Status updated on  16.12.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Northwestern University
633 Clark Street
Evanston, IL 60208 / US
[2016/07]
Inventor(s)01 / MOSKAL, Joseph
801 Central Street
Evanston, IL Illinois 60201 / US
 [2016/07]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2019/01]
Former [2016/07]Lau, Sarah Jane, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date15171991.105.10.2010
[2016/07]
Priority number, dateUS20090248650P05.10.2009         Original published format: US 248650 P
[2016/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2985032
Date:17.02.2016
Language:EN
[2016/07]
Type: B1 Patent specification 
No.:EP2985032
Date:02.01.2019
Language:EN
[2019/01]
Search report(s)(Supplementary) European search report - dispatched on:EP18.01.2016
ClassificationIPC:A61K38/10, A61P25/22, A61P25/24
[2016/07]
CPC:
A61K38/07 (EP); A61P25/00 (EP); A61P25/22 (EP);
A61P25/24 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/39]
Former [2016/07]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:GLYX ZUR VERWENDUNG BEI DER BEHANDLUNG VON ALZHEIMERKRANKHEIT, PARKINSONKRANKHEIT ODER HUNTINGTONKRANKHEIT[2018/30]
English:GLYX FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE[2018/30]
French:GLYX POUR UNE UTILISATION DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER, LA MALADIE DE PARKINSON OU LA MALADIE DE HUNTINGTON[2018/30]
Former [2016/09]GLYX ZUR VERWENDUNG BEI DER BEHANDLUNG VON ALZHEIMERKRANKHEIT, AIDS DEMENTIA, PARKINSONKRANKHEIT ODER HUNTINGTONKRANKHEIT
Former [2016/07]GLYX FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE, AIDS DEMENTIA, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE
Former [2016/07]GLYX POUR UNE UTILISATION DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER, LA DEMENCE DU SIDA, LA MALADIE DE PARKINSON OU LA MALADIE DE HUNTINGTON
Examination procedure16.08.2016Examination requested  [2016/39]
17.08.2016Amendment by applicant (claims and/or description)
07.02.2017Despatch of a communication from the examining division (Time limit: M04)
12.05.2017Reply to a communication from the examining division
03.07.2017Despatch of a communication from the examining division (Time limit: M04)
08.11.2017Reply to a communication from the examining division
03.01.2018Despatch of a communication from the examining division (Time limit: M04)
11.05.2018Reply to a communication from the examining division
16.07.2018Communication of intention to grant the patent
26.11.2018Fee for grant paid
26.11.2018Fee for publishing/printing paid
26.11.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10822514.5  / EP2485751
EP14169137.8  / EP2813236
Divisional application(s)EP18248179.6  / EP3488856
EP21159885.9   Application deemed to be withdrawn  : 02.04.2021
Opposition(s)03.10.2019No opposition filed within time limit [2019/50]
Fees paidRenewal fee
12.06.2015Renewal fee patent year 03
12.06.2015Renewal fee patent year 04
12.06.2015Renewal fee patent year 05
27.10.2015Renewal fee patent year 06
27.10.2016Renewal fee patent year 07
27.10.2017Renewal fee patent year 08
29.10.2018Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL02.01.2019
CY02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
MK02.01.2019
MT02.01.2019
RS02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
[2022/31]
Former [2021/34]AL02.01.2019
CY02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
MT02.01.2019
RS02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
Former [2021/26]AL02.01.2019
CY02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
RS02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
Former [2020/29]AL02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
MC02.01.2019
RS02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
Former [2020/13]AL02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
RS02.01.2019
SI02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
Former [2019/51]AL02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
RS02.01.2019
SK02.01.2019
SM02.01.2019
BG02.04.2019
IS02.05.2019
Former [2019/49]AL02.01.2019
EE02.01.2019
FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
RS02.01.2019
SK02.01.2019
BG02.04.2019
IS02.05.2019
Former [2019/39]FI02.01.2019
HR02.01.2019
LT02.01.2019
LV02.01.2019
RS02.01.2019
BG02.04.2019
IS02.05.2019
Former [2019/38]FI02.01.2019
LT02.01.2019
BG02.04.2019
Former [2019/33]FI02.01.2019
LT02.01.2019
Documents cited:Search[Y]WO02072609  (NYXIS NEUROTHERAPIES INC [US], et al) [Y] 1-3 * the whole document * * example 4 * * page 20, line 25 - page 21, line 21 * * claims 20-27 *;
 [XP]  - CRANE A ET AL, "Reduction of cognitive deficits in the HD 51 CAG rat model of Huntington's disease with a NMDA receptor partial agonist, GLYX-13", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, (20111114), vol. 41, ISSN 0190-5295, XP009166597 [XP] 1-3 * the whole document *
 [XP]  - WOLFRAM-ADUAN A ET AL, "Globus pallidus neurochemical responses to the partial NMDA agonist GLYX-13 among HD51(CAG) Huntington's disease model rats", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, (20110101), vol. 41, ISSN 0190-5295, XP009166606 [XP] 1-3 * the whole document *
 [Y]  - STANTON PATRIC K ET AL, "Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13", NEUROREPORT, LIPPINCOTT WILLIAMS & WILKINS, UK, (20090801), vol. 20, no. 13, doi:10.1097/WNR.0B013E32832F5130, ISSN 0959-4965, pages 1193 - 1197, XP009166611 [Y] 1-3 * the whole document * * Conclusion; page 1197 *

DOI:   http://dx.doi.org/10.1097/WNR.0b013e32832f5130
 [Y]  - MOSKAL J R ET AL, "GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 49, no. 7, ISSN 0028-3908, (20051201), pages 1077 - 1087, (20051201), XP027632781 [Y] 1-3 * the whole document * * 3.6 In vivo learning studies; page 1082, column l - page 1084, column l *
 [Y]  - ZHANG X L ET AL, "A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 55, no. 7, doi:10.1016/J.NEUROPHARM.2008.08.018, ISSN 0028-3908, (20081201), pages 1238 - 1250, (20080829), XP025585049 [Y] 1-3 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2008.08.018
 [T]  - BURGDORF JEFFREY ET AL, "The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats", NEUROBIOLOGY OF AGING, USA, (20110401), vol. 32, no. 4, doi:10.1016/J.NEUROBIOLAGING.2009.04.012, ISSN 1558-1497, pages 698 - 706, XP009166613 [T] 1-3 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.neurobiolaging.2009.04.012
 [Y]  - KRYSTAL J H ET AL, "NMDA AGONISTS AND ANTAGONISTS AS PROBES OF GLUTAMATERGIC DYSFUNCTION AND PHARMACOTHERAPIES IN NEUROPSYCHIATRIC DISORDERS", HARVARD REVIEW OF PSYCHIATRY, ST. LOUIS, MO, US, (19990101), vol. 7, no. 3, doi:10.1093/HRP/7.3.125, ISSN 1067-3229, pages 125 - 143, XP008048548 [Y] 1-3 * page 127; table 1 * * page 127, column r, paragraph 2 - page 129, column l, paragraph 1 * * page 131, column l, paragraph 2 - column r, paragraph l * * page 132; figure 1 *

DOI:   http://dx.doi.org/10.1093/hrp/7.3.125
by applicantUS4086196
 US5763393
 US6107271
    - BLISS; COLLINGRIDGE, NATURE, (1993), vol. 361, pages 31 - 39
    - MUIR; LEES, STROKE, (1995), vol. 26, pages 503 - 513
    - MOTHET ET AL., PROC. NAT. ACAD. SCI., (2000), vol. 97, pages 4926 - 4931
    - KOZIKOWSKI ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (1990), vol. 33, pages 1561 - 1571
    - RUSH ET AL., AM. J. PSYCHIATRY, (2006), vol. 163, page 1905
    - WOOD ET AL., NEUROREPORT, (2008), vol. 19, pages 1059 - 1061
    - LEESON; IVERSEN, J. MED. CHEM., (1994), vol. 37, pages 4053 - 4067
    - BRISTOW ET AL., JPET, (1996), vol. 279, pages 492 - 501
    - PARSONS ET AL., JPET, (1997), vol. 283, pages 1264 - 1275
    - GARCIA ET AL., PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (2008), vol. 32, pages 140 - 144
    - TREIT D; FUNDYTUS M, "Thigmotaxis as a test for anxiolytic activity in rats", PHARMACHOL BIOCHEM BEHAV, (1989), vol. 31, doi:doi:10.1016/0091-3057(88)90413-3, pages 959 - 62, XP025521052

DOI:   http://dx.doi.org/10.1016/0091-3057(88)90413-3
    - BURGDORF, J.; PANKSEPP, J.; BRUDZYNSKI, S.M.; KROES, R.A.; MOSKAL, J.R., "The effect of selective breeding for differential rates of 50-kHz ultrasonic vocalizations on emotional behavior in rats", DEVEL. PSYCHOBIOLOGY, (2008), vol. 51, pages 34 - 46
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.